1
|
Keeley PW, Trod S, Gamboa BN, Coffey PJ, Reese BE. Nfia Is Critical for AII Amacrine Cell Production: Selective Bipolar Cell Dependencies and Diminished ERG. J Neurosci 2023; 43:8367-8384. [PMID: 37775301 PMCID: PMC10711738 DOI: 10.1523/jneurosci.1099-23.2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2023] [Revised: 09/20/2023] [Accepted: 09/21/2023] [Indexed: 10/01/2023] Open
Abstract
The nuclear factor one (NFI) transcription factor genes Nfia, Nfib, and Nfix are all enriched in late-stage retinal progenitor cells, and their loss has been shown to retain these progenitors at the expense of later-generated retinal cell types. Whether they play any role in the specification of those later-generated fates is unknown, but the expression of one of these, Nfia, in a specific amacrine cell type may intimate such a role. Here, Nfia conditional knockout (Nfia-CKO) mice (both sexes) were assessed, finding a massive and largely selective absence of AII amacrine cells. There was, however, a partial reduction in type 2 cone bipolar cells (CBCs), being richly interconnected to AII cells. Counts of dying cells showed a significant increase in Nfia-CKO retinas at postnatal day (P)7, after AII cell numbers were already reduced but in advance of the loss of type 2 CBCs detected by P10. Those results suggest a role for Nfia in the specification of the AII amacrine cell fate and a dependency of the type 2 CBCs on them. Delaying the conditional loss of Nfia to the first postnatal week did not alter AII cell number nor differentiation, further suggesting that its role in AII cells is solely associated with their production. The physiological consequences of their loss were assessed using the ERG, finding the oscillatory potentials to be profoundly diminished. A slight reduction in the b-wave was also detected, attributed to an altered distribution of the terminals of rod bipolar cells, implicating a role of the AII amacrine cells in constraining their stratification.SIGNIFICANCE STATEMENT The transcription factor NFIA is shown to play a critical role in the specification of a single type of retinal amacrine cell, the AII cell. Using an Nfia-conditional knockout mouse to eliminate this population of retinal neurons, we demonstrate two selective bipolar cell dependencies on the AII cells; the terminals of rod bipolar cells become mis-stratified in the inner plexiform layer, and one type of cone bipolar cell undergoes enhanced cell death. The physiological consequence of this loss of the AII cells was also assessed, finding the cells to be a major contributor to the oscillatory potentials in the electroretinogram.
Collapse
Affiliation(s)
- Patrick W Keeley
- Neuroscience Research Institute, University of California, Santa Barbara, California 93106-5060
| | - Stephanie Trod
- Neuroscience Research Institute, University of California, Santa Barbara, California 93106-5060
| | - Bruno N Gamboa
- Neuroscience Research Institute, University of California, Santa Barbara, California 93106-5060
| | - Pete J Coffey
- Neuroscience Research Institute, University of California, Santa Barbara, California 93106-5060
| | - Benjamin E Reese
- Neuroscience Research Institute, University of California, Santa Barbara, California 93106-5060
- Department of Psychological and Brain Sciences, University of California, Santa Barbara, California 93106-5060
| |
Collapse
|
2
|
Moschetti V, Schlecker C, Wind S, Goetz S, Schmitt H, Schultz A, Liesenfeld KH, Wunderlich G, Desch M. Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics. Clin Drug Investig 2018; 38:737-750. [PMID: 29846887 PMCID: PMC6061410 DOI: 10.1007/s40261-018-0660-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Background and Objective Schizophrenia and Alzheimer’s disease are characterised by abnormalities in glutamatergic pathways related to N-methyl-d-aspartate receptor hypofunction. Glycine is an N-methyl-d-aspartate receptor co-agonist; inhibition of glycine transporter 1 may improve N-methyl-d-aspartate receptor function. This phase I, randomised, two-part study evaluated the safety, tolerability and pharmacokinetic profile of BI 425809, a novel glycine transporter 1 inhibitor, in healthy male and female volunteers. Methods Part 1 evaluated BI 425809 10, 25, 50 or 75 mg once daily or 75 mg twice daily in young subjects, and 25 mg or 50 mg once daily in elderly subjects. Each dose group comprised 12 subjects who received BI 425809 (n = 9) or placebo (n = 3) for 14 days (day 1: single dose; days 4–14: multiple dosing). Part 2 compared pharmacokinetic profiles in 12 subjects who received a single dose of BI 425809 25 mg in the morning and evening. Results Pharmacokinetic profiles were similarly shaped for all dose groups. Median time to maximum plasma concentration was 3.0–4.5 h with steady state being reached between days 6 and 10. Pharmacokinetic parameters demonstrated dose linearity at the predicted therapeutic exposure range of BI 425809 ≤ 25 mg once daily, but increased less than dose proportionally for ≥ 50 mg once daily. All reported adverse events were of mild-to-moderate intensity, 51/84 (61%; part 1) subjects had one or more treatment-related adverse event, no serious adverse events occurred and no dose dependency was observed. Conclusions Pharmacokinetic properties support both morning and evening dosing. BI 425809 was generally well tolerated at all tested doses. Clinicaltrials.gov identifier NCT02337283. Electronic supplementary material The online version of this article (10.1007/s40261-018-0660-2) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
| | | | - Sven Wind
- Boehringer Ingelheim International GmbH, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany
| | - Sophia Goetz
- Boehringer Ingelheim International GmbH, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany
| | - Holger Schmitt
- Boehringer Ingelheim International GmbH, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany
| | - Armin Schultz
- CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
| | - Karl-Heinz Liesenfeld
- Boehringer Ingelheim International GmbH, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany
| | | | - Michael Desch
- Boehringer Ingelheim International GmbH, Birkendorfer Str. 65, 88397, Biberach an der Riss, Germany.
| |
Collapse
|
4
|
Dai J, He J, Wang G, Wang M, Li S, Yin ZQ. Contribution of GABAa, GABAc and glycine receptors to rat dark-adapted oscillatory potentials in the time and frequency domain. Oncotarget 2017; 8:77696-77709. [PMID: 29100418 PMCID: PMC5652335 DOI: 10.18632/oncotarget.20770] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2017] [Accepted: 07/29/2017] [Indexed: 02/02/2023] Open
Abstract
Retinal oscillatory potentials (OPs) consist of a series of relatively high-frequency rhythmic wavelets, superimposed onto the ascending phase of the b-wave of the electroretinogram (ERG). However, the origin of OPs is uncertain and methods of measurement of OPs are diverse. In this study, we first isolated OPs from the rat ERG and fitted them with Gabor functions and found that the envelope of the OP contained information about maximum amplitude and time-to-peak to enable satisfactory quantification of the later OPs. And the OP/b-wave ratio should be evaluated to exclude an effect of the b-wave on the OPs. Next, we recorded OPs after intravitreal injection of 2-amino-4-phosphonobutyric acid (APB), tetrodotoxin (TTX), γ-aminobutyric acid (GABA), strychnine (STR), SR95531 (SR), isoguvacine (ISO), (1,2,5,6-tetrahydropyridin-4-yl) methylphosphinic acid (TPMPA) and GABA+TPMPA. We showed that GABA and APB only removed the later OPs, when compared to control eyes. TTX delayed the peak time, and STR, SR and ISO reduced the amplitude of OPs. TPMPA delayed the peak time but increased the ratio of OPs to b-wave. Furthermore, administration of combined GABA and TPMPA caused the later OPs to increase in amplitude with time, compared with those after delivery of GABA alone. Finally, we observed that GABAc and glycine receptors contributed to a low-frequency component of the OPs, while GABAa contributed to both components. These results suggest that the early components of the OPs are mainly generated by the photoreceptors, whilst the later components are mainly regulated by GABAa, GABAc and glycine receptors.
Collapse
Affiliation(s)
- Jiaman Dai
- College of Bioengineering, Chongqing University, Chongqing 400030, China.,Key Lab of Visual Damage and Regeneration & Restoration of Chongqing, Chongqing 400038, China
| | - Juncai He
- Key Lab of Visual Damage and Regeneration & Restoration of Chongqing, Chongqing 400038, China.,Southwest Hospital/Southwest Eye Hospital, Third Military Medical University, Chongqing 400038, China
| | - Gang Wang
- Key Lab of Visual Damage and Regeneration & Restoration of Chongqing, Chongqing 400038, China.,Southwest Hospital/Southwest Eye Hospital, Third Military Medical University, Chongqing 400038, China
| | - Min Wang
- Key Lab of Visual Damage and Regeneration & Restoration of Chongqing, Chongqing 400038, China.,Southwest Hospital/Southwest Eye Hospital, Third Military Medical University, Chongqing 400038, China
| | - Shiying Li
- Key Lab of Visual Damage and Regeneration & Restoration of Chongqing, Chongqing 400038, China.,Southwest Hospital/Southwest Eye Hospital, Third Military Medical University, Chongqing 400038, China
| | - Zheng Qin Yin
- College of Bioengineering, Chongqing University, Chongqing 400030, China.,Key Lab of Visual Damage and Regeneration & Restoration of Chongqing, Chongqing 400038, China.,Southwest Hospital/Southwest Eye Hospital, Third Military Medical University, Chongqing 400038, China
| |
Collapse
|
5
|
Liu CN, Peng Q, Yates DW, Huang W, Devantier H, Aguirre SA. Ocular safety assessment of sodium iodate in cynomolgus monkeys. TOXICOLOGY RESEARCH AND APPLICATION 2017. [DOI: 10.1177/2397847317696370] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Although sodium iodate (NaIO3)-induced retinal injury model has been widely used in rodents, its application in large animal species has encountered variation in retinal toxicity. NaIO3 induced retinal degeneration and functional changes in sheep, but not in swine. In monkeys, administration of NaIO3 via a carotid artery affected only the cell function of ipsilateral retinal pigment epithelium. The aim of the present study was to identify the dosage and route of NaIO3 administration resulting in morphologic and functional retinal changes in cynomolgus monkeys. Separate groups of animals received NaIO3 intravenously in three different dosing paradigms. Vehicle control animals received phosphate-buffered saline. At selected time points following dosing, flash electroretinograms (ERGs) were recorded followed by necropsy. The eyes were examined microscopically post-necropsy and the levels of circulating microRNA-183 cluster were evaluated in the blood samples collected on days 1, 4, and 5 postdose. A statistically significant reduction in both scotopic a-wave and scotopic and photopic b-wave signals ( p < 0.05) were observed between the ERG signals acquired from NaIO3-treated and vehicle control animals, coupled with time-dependent elevations in plasma miR-183 cluster. Mild to moderate retinal degeneration was observed in the outer layer of the retina, which correlated well with the functional and clinical observations. There were no statistically significant differences in scotopic oscillatory potentials. These findings suggest that intravenous injection of sublethal NaIO3 markedly damaged the cone and rod photoreceptors both functionally and morphologically, and plasma miR-183 reflected the retinal toxicity in those animals with moderate retinal damage.
Collapse
Affiliation(s)
- Chang-Ning Liu
- Department of Investigative Toxicology, Drug Safety Research & Development, Pfizer Worldwide R&D, Groton, CT, USA
| | - Qinghai Peng
- Drug Safety Research & Development, Pfizer Worldwide R&D, La Jolla, CA, USA
| | - David W Yates
- Worldwide Comparative Medicine, Pfizer Worldwide R&D, Pearl River, NY, USA
| | - Wenhu Huang
- Drug Safety Research & Development, Pfizer Worldwide R&D, La Jolla, CA, USA
| | - Heather Devantier
- Worldwide Comparative Medicine, Pfizer Worldwide R&D, Pearl River, NY, USA
| | - Shirley A Aguirre
- Drug Safety Research & Development, Pfizer Worldwide R&D, La Jolla, CA, USA
| |
Collapse
|
6
|
Liu CN, Mathialagan N, Lappin P, Fortner J, Somps C, Seitis G, Johnson TR, Hu W, Matsumoto D. Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition. Toxicol Sci 2014; 143:116-25. [PMID: 25326243 DOI: 10.1093/toxsci/kfu213] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Crizotinib (Xalkori) is a tyrosine kinase inhibitor of both anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition factor (c-Met). Though not predicted from standard nonclinical toxicological evaluation, visual disturbance became a frequently observed adverse event in humans. To understand the possible mechanism of this vision effect, an in vivo electroretinogram (ERG) study was conducted to assess retinal functional changes following oral administration of crizotinib. Immunohistochemical (IHC) staining of ALK and c-Met in the neural retinas of human, non-human primate, dog, rat, and mouse was used to aid in the animal model selection. ALK IHC staining was identified predominantly in the ganglion cell and inner nuclear layers of most species evaluated, in the inner plexiform layer in human and rodent, and in the nerve fiber layer in human and rat only. There was no apparent staining of any layer of the neural retina for c-Met in any of the species evaluated. ERG measurements identified a significant reduction in b-wave amplitude during the initial phase of dark adaptation in the crizotinib-treated rats. ERGs were also taken following oral administration of PF-06463922 (an ALK-selective inhibitor), for an understanding of potential kinase involvement. ERG effects were not observed in PF-06463922-treated animals when comparable exposures in the vitreous humor were achieved. Collectively, our results suggest that the ERG b-wave amplitude decreases during dark adaption following crizotinib administration may be related to signaling changes within the retina in rats, likely independent of ALK inhibition.
Collapse
Affiliation(s)
- Chang-Ning Liu
- *Investigative Toxicology, Drug Safety R&D, Pfizer Inc., Groton 06340, Connecticut, Drug Safety R&D, Pfizer Inc., San Diego, CA 92121, Comparative Medicine, Pfizer Inc., Groton 06340, Connecticut and Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc., San Diego, CA 92121
| | - Nagappan Mathialagan
- *Investigative Toxicology, Drug Safety R&D, Pfizer Inc., Groton 06340, Connecticut, Drug Safety R&D, Pfizer Inc., San Diego, CA 92121, Comparative Medicine, Pfizer Inc., Groton 06340, Connecticut and Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc., San Diego, CA 92121
| | - Patrick Lappin
- *Investigative Toxicology, Drug Safety R&D, Pfizer Inc., Groton 06340, Connecticut, Drug Safety R&D, Pfizer Inc., San Diego, CA 92121, Comparative Medicine, Pfizer Inc., Groton 06340, Connecticut and Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc., San Diego, CA 92121
| | - Jay Fortner
- *Investigative Toxicology, Drug Safety R&D, Pfizer Inc., Groton 06340, Connecticut, Drug Safety R&D, Pfizer Inc., San Diego, CA 92121, Comparative Medicine, Pfizer Inc., Groton 06340, Connecticut and Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc., San Diego, CA 92121
| | - Chris Somps
- *Investigative Toxicology, Drug Safety R&D, Pfizer Inc., Groton 06340, Connecticut, Drug Safety R&D, Pfizer Inc., San Diego, CA 92121, Comparative Medicine, Pfizer Inc., Groton 06340, Connecticut and Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc., San Diego, CA 92121
| | - Gary Seitis
- *Investigative Toxicology, Drug Safety R&D, Pfizer Inc., Groton 06340, Connecticut, Drug Safety R&D, Pfizer Inc., San Diego, CA 92121, Comparative Medicine, Pfizer Inc., Groton 06340, Connecticut and Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc., San Diego, CA 92121
| | - Theodore R Johnson
- *Investigative Toxicology, Drug Safety R&D, Pfizer Inc., Groton 06340, Connecticut, Drug Safety R&D, Pfizer Inc., San Diego, CA 92121, Comparative Medicine, Pfizer Inc., Groton 06340, Connecticut and Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc., San Diego, CA 92121
| | - Wenyue Hu
- *Investigative Toxicology, Drug Safety R&D, Pfizer Inc., Groton 06340, Connecticut, Drug Safety R&D, Pfizer Inc., San Diego, CA 92121, Comparative Medicine, Pfizer Inc., Groton 06340, Connecticut and Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc., San Diego, CA 92121
| | - Diane Matsumoto
- *Investigative Toxicology, Drug Safety R&D, Pfizer Inc., Groton 06340, Connecticut, Drug Safety R&D, Pfizer Inc., San Diego, CA 92121, Comparative Medicine, Pfizer Inc., Groton 06340, Connecticut and Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc., San Diego, CA 92121
| |
Collapse
|